Company Filing History:
Years Active: 2021
Title: Meidai Sun - Innovator in Immunotherapy
Introduction
Meidai Sun is a prominent inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly through his innovative research and development of novel peptides.
Latest Patents
Meidai Sun holds a patent for "Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules." This invention relates to novel peptides derived from TRPM1, complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. The patent also includes binding moieties that bind to the peptides and/or complexes, which are useful for developing immunotherapeutic reagents for treating diseases such as cancer. He has 1 patent to his name.
Career Highlights
Throughout his career, Meidai Sun has worked with notable companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His work has focused on advancing the understanding and application of immunotherapeutic strategies.
Collaborations
Meidai Sun has collaborated with esteemed colleagues such as Alex Powlesland and Maurits Kleijnen, contributing to the advancement of research in his field.
Conclusion
Meidai Sun's innovative work in immunotherapy and his patented inventions highlight his significant role in advancing medical science. His contributions are paving the way for new treatments in the fight against diseases like cancer.